|
Daily Medical Update
Dementia & Mild Cognitive Impairment (Screening, AD)
Monday, February 16, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Alzheimer's & Dementia (2025) - Systematic Review/Meta-Analysis
Key Findings
- Across 49 studies, pooled sensitivity ranged from 49.3% to 91.4% and pooled specificity from 61.5% to 96.7%, showing large between-assay performance differences.
- Post-test probability shifts varied substantially by baseline pre-test probability and assay, indicating that results improve decision-making most when integrated with structured clinical assessment.
📋 Practice Implication: In primary care cognitive workups, use blood biomarkers as a triage/rule-in tool tied to pre-test probability and local assay performance rather than as a standalone diagnostic endpoint.
|
Ageing Research Reviews (2026) - Systematic Review/Meta-Analysis
Key Findings
- In pooled anti-amyloid trial data (N=5633), ApoE4 carriers had higher ARIA-E risk (RR 2.19, 95% CI 1.91-2.50) and higher ARIA-H risk (RR 3.45, 95% CI 1.35-8.72) versus non-carriers.
- Treatment effects and quality-of-life gains differed across subgroups, supporting more personalized selection rather than uniform referral for all early AD presentations.
📋 Practice Implication: Before referral for anti-amyloid treatment, discuss ApoE-linked safety tradeoffs explicitly and prioritize shared decision-making with memory specialists.
|
Journal of Prevention of Alzheimer's Disease (2026) - Randomized Trial Extension
Key Findings
- At 3 years, early-start donanemab was associated with slower CDR-SB progression versus weighted external controls (-1.2 points, 95% CI -1.7 to -0.7).
- Early-start participants showed lower progression risk on CDR-Global versus delayed-start treatment (HR 0.73, p<0.001), consistent with benefit from earlier treatment window entry.
📋 Practice Implication: For eligible symptomatic patients, expedite specialty evaluation to avoid delaying potential disease-modifying benefit.
|
Revue Neurologique (2026) - Systematic Review/Meta-Analysis
Key Findings
- Across 5 RCTs (n=540), intranasal insulin showed no significant cognitive advantage versus placebo on ADAS-Cog13 (mean difference -1.09, 95% CI -4.89 to 2.71).
- No significant improvement occurred in activities of daily living or key CSF biomarkers, while adverse-event burden did not show a compelling net benefit signal.
📋 Practice Implication: Do not add intranasal insulin for cognitive benefit outside trials; focus on proven supportive care and evidence-based referral pathways.
|
Neurological Sciences (2026) - Meta-Analysis of RCTs
Key Findings
- Meta-analysis of 4 RCTs found no significant cognitive benefit versus placebo (pooled SMD -0.10, 95% CI -0.53 to 0.34).
- ADAS-Cog analyses were similarly neutral (SMD 0.07, 95% CI -0.47 to 0.62), indicating no practice-ready efficacy signal for cognition in this population.
📋 Practice Implication: Avoid prescribing GLP-1 RAs specifically for cognition in non-diabetic MCI/AD until stronger efficacy data emerge.
|
|
New high-yield evidence supports blood-based Alzheimer biomarker use as a practical diagnostic triage step, while reinforcing that test performance is assay-specific and must be interpreted with clinical pre-test probability. For disease-modifying anti-amyloid therapy, genotype-linked safety risk (especially ApoE4-associated ARIA) is now central to counseling and referral decisions. Several candidate therapies (intranasal insulin, GLP-1 RA use in non-diabetic MCI/AD) showed no meaningful cognitive benefit, helping primary care avoid low-value prescribing.
|
|